New pyrano-pyridine conjugates as potential anticancer agents: design, synthesis and computational studies
Compared to erlotinib (IC<sub>50</sub> = 0.18 µM), compounds 8a and 8b demonstrated the highest anticancer activity with IC<sub>50</sub> Values 0.23 and 0.15 µM, respectively). Further, derivative 8a illustrated encouraging inhibitory characteristics against EGFR and VEGFR-2 (IC<sub>50</sub> = 1.21 and 2.65 μM, respectively). A computational study was used to estimate the physicochemical and pharmacokinetic properties to afford insightful information about the newly synthesized agents.
Authors
- Heba S. A. Elzahabi (ORCID: https://orcid.org/0000-0002-7023-6364)
- Aladdin M. Srour (ORCID: https://orcid.org/0000-0002-6692-6952)
- Eman Samir Nossier (ORCID: https://orcid.org/0000-0001-6159-5333)
- Hanem M. Awad (ORCID: https://orcid.org/0000-0002-3970-2371)
- Najla Altwaijry (ORCID: https://orcid.org/0000-0001-6372-7141)
- Sherief Mousa
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- Al-Azhar University (EG)
- Academy of Scientific Research and Technology (EG)
- National Research Centre (EG)
Publication Details
- Journal
- Future Medicinal Chemistry
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1080/17568919.2024.2431475
- Citations
- 7
- Primary Topic
- Synthesis and biological activity
- Type
- article
- Field-Weighted Citation Impact
- 1.75
Funders
- National Research Centre
- Princess Nourah Bint Abdulrahman University